Multiple myeloma incidence and mortality trends in the United States, 1999–2020
Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of
hematologic malignancies. There is limited epidemiological evidence regarding the long …
hematologic malignancies. There is limited epidemiological evidence regarding the long …
Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities
R Heestermans, R Schots, A De Becker… - International Journal of …, 2024 - mdpi.com
Over the last decades, the survival of multiple myeloma (MM) patients has considerably
improved. However, despite the availability of new treatments, most patients still relapse and …
improved. However, despite the availability of new treatments, most patients still relapse and …
Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach
CR Flowers, RW Anantha, V Leautaud… - Blood Cancer …, 2025 - aacrjournals.org
Hematologic malignancies exhibit disparities in risk and outcomes across populations. A
systematic review to identify prospective studies addressing disparities among patients with …
systematic review to identify prospective studies addressing disparities among patients with …
Asymptomatic incidence of monoclonal gammopathy of undetermined significance and preclinical duration to myeloma diagnosis: a modeling study
Background: Monoclonal gammopathy of undetermined significance (MGUS) is the
premalignant condition of multiple myeloma. Given a lack of population-based screening for …
premalignant condition of multiple myeloma. Given a lack of population-based screening for …
N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair
S Jiang, L Gao, J Li, F Zhang, Y Zhang… - Frontiers in Cell and …, 2024 - frontiersin.org
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by
the abnormalities of various molecules and microenvironments. Exploring these resistance …
the abnormalities of various molecules and microenvironments. Exploring these resistance …
Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among …
Background In patients with diabetes and monoclonal gammopathy of uncertain significance
(MGUS), the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on the natural …
(MGUS), the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on the natural …
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and …
M Mahesri, A Sarpatwari, KF Huybrechts, J Lii, SB Lee… - Drug Safety, 2024 - Springer
Objective We evaluated dispensing trends of lenalidomide, pomalidomide, and thalidomide
and assessed adherence to REMS pregnancy testing requirements among at-risk patients …
and assessed adherence to REMS pregnancy testing requirements among at-risk patients …
Associations between patient characteristics and progression to multiple myeloma among patients with monoclonal gammopathy of undetermined significance: A …
Y Li, SH Hsu, R Wang, P Theprungsirikul… - … Myeloma and Leukemia, 2024 - Elsevier
Background Monoclonal gammopathy of undetermined significance (MGUS) is a pre-
malignant condition of multiple myeloma (MM). Evidence suggested old age, black race …
malignant condition of multiple myeloma (MM). Evidence suggested old age, black race …
[PDF][PDF] A Comprehensive Review on Unravelling the Complexity of Blood Cancer
S Saha, S Ghosh, S Ghosh, S Nandi - blood - academia.edu
Blood cancer also referred to as haematological carcinoma, is a large category of
malignancies that affects the bone marrow, lymphatic as well as blood systems. This …
malignancies that affects the bone marrow, lymphatic as well as blood systems. This …